Peritoneal Mesothelioma: Multi-Drug HIPEC Combo Leads to Better Outcomes

A new French study suggests that peritoneal mesothelioma patients who undergo CRS/HIPEC treatment  have better outcomes when two chemotherapeutic agents are used instead of just one. The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) has dramatically improved the prognosis for patients with peritoneal mesothelioma, a rare form of the asbestos cancer that occurs in the abdomen. But a team of researchers from cancer hospitals across France wanted to know if outcomes are better with some HIPEC drugs than they are with others. Their results seem to show a clear mesothelioma survival advantage to platinum-based regimens (those including cisplatin) that include at least one other agent. Treating a Rare Type of Mesothelioma During CRS, surgeons remove … Continue reading Peritoneal Mesothelioma: Multi-Drug HIPEC Combo Leads to Better Outcomes »

New Staging Method May Improve Accuracy of Mesothelioma Prognosis

Pleural mesothelioma patients may be less likely to get a true picture of their prognosis when their cancer is “staged” using the standard TNM method. Harvard researchers came to that conclusion after comparing the actual clinical status of 472 malignant pleural mesothelioma patients (their cTNM stage) with their TNM stage as determined by pathological analysis (pTNM). They found a significant discrepancy between clinical and pathological mesothelioma stage – and, as a result, in mesothelioma prognosis – in 6 out of 10 patients.   TNM Staging for Malignant Mesothelioma The TNM staging criteria is a method for determining how extensive a patient’s cancer is by evaluating three parameters: tumor size (T), involvement of the lymph nodes (N), and the extent of … Continue reading New Staging Method May Improve Accuracy of Mesothelioma Prognosis »

Does Alcohol Increase Mesothelioma Risk?

A new study suggests that drinking too much could raise the risk for developing malignant mesothelioma or another type of cancer. Surprisingly, not drinking quite enough appears to do the same thing. The study was conducted by public health researchers in Northern Ireland and at the National Cancer Institute in the US. It included data from nearly 100,000 adults between 55 and 74 participating in the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. To better understand how alcohol impacts cancer development, researchers assessed the overall risk of death among the study subjects, as well as the risk of death specifically from cancer, and compared it with reported average lifetime alcohol consumption. “In comparison to lifetime light alcohol … Continue reading Does Alcohol Increase Mesothelioma Risk? »

Study Finds Chemotherapy Unlikely to Improve Peritoneal Mesothelioma Survival

A new study from the University of Illinois suggests that patients with peritoneal mesothelioma who undergo  surgery may not get any benefit from having chemotherapy, too. Mesothelioma patients who have cytoreductive surgery, which is also called debulking surgery, tend to live more than four times as long as those who do not have the surgery. Rinsing the abdominal cavity with a heated solution of cancer-killing drugs may improve survival even more. But, according to the new study, the same cannot be said of chemotherapy drugs that are delivered orally or by injection or infusion so that they circulate through the whole body (systemic chemotherapy). Peritoneal Mesothelioma and Cytoreductive Surgery Peritoneal mesothelioma is a fast-growing malignancy that occurs on the membrane … Continue reading Study Finds Chemotherapy Unlikely to Improve Peritoneal Mesothelioma Survival »

PD-L1 Linked to Shorter Mesothelioma Survival

Mesothelioma consultation regarding treatment

Mesothelioma patients who express too much of the protein PD-L1 are less likely to survive the asbestos cancer than those whose cells express less. That is the message from a new Australian study on mesothelioma prognosis, which backs up the findings from a number of previous PD-L1 studies. In a report published in the Asia-Pacific Journal of Clinical Oncology, oncologist Bella Hai Nguyen and colleagues at The Canberra Hospital in Garran analyzed the clinical data on 58 malignant pleural mesothelioma patients treated there between 2006 and 2016. As with previous studies on PD-L1, the Australian study found a link between overexpression of the protein and poor mesothelioma survival. Unlike other studies, though, the new study finds that an even higher … Continue reading PD-L1 Linked to Shorter Mesothelioma Survival »

Immunotherapy for Mesothelioma: Who Are the Best Candidates?

Immunotherapy is emerging as one of the most promising new treatment approaches for a wide range of cancers, including malignant pleural mesothelioma, the treatment-resistant lung-related cancer caused by asbestos exposure. Every year, more than 2,500 Americans are diagnosed with pleural mesothelioma. Most will die of the illness within 18 months, even with the most advanced chemotherapeutic, radiotherapeutic, and surgical treatments. But immunotherapy, which recruits the body’s own immune system to help fight the cancer, may be a more effective option for some mesothelioma patients. Now, a new study conducted by researchers in Italy, with support from California-based Genentech, suggests that there may be a way to identify which mesothelioma patients are most likely to benefit from immunotherapy. Molecular and Histopathological … Continue reading Immunotherapy for Mesothelioma: Who Are the Best Candidates? »

New Assessment Identifies People at High Risk for Malignant Mesothelioma

Black American Patient

Scottish researchers say they have come up with a better way to decide which asbestos-exposed people might benefit from mesothelioma screening or even mesothelioma prevention measures. They have developed an assessment tool to gather detailed information from workers about the time, duration, and nature of their asbestos exposure in order to better quantify their mesothelioma risk. “The assessment is based on the tasks carried out and includes parameters for substance emission potential, activity emission potential, the effectiveness of any local control measures, passive emission, the fractional time the asbestos source is active, and the efficiency of any respiratory protection worn,” writes lead author John W, Cherrie with the Institute of Occupational Medicine in Edinburgh. Measuring Asbestos Exposure Asbestos is the … Continue reading New Assessment Identifies People at High Risk for Malignant Mesothelioma »

New Chemotherapy Technique Carries Risks for Peritoneal Mesothelioma Patients

A new way of delivering chemotherapy drugs to the site of a peritoneal mesothelioma tumor has some unique benefits, but can also be risky. The technique, called pressurized intraperitoneal aerosol chemotherapy (PIPAC) allows doctors to “spray” a solution of chemotherapy drugs directly onto peritoneal tumors through small ports in the abdomen. The intention is to uniformly coat the tumor and help keep chemotherapy drugs in contact with malignant mesothelioma or other peritoneal cancer cells for as long as possible. Testing PIPAC for Unresectable Mesothelioma The PIPAC technique is being pioneered in Europe. In a new French study, doctors tested it in 73 patients who had peritoneal mesothelioma or metastatic colorectal, gastric, or ovarian cancer on the peritoneal membrane lining the … Continue reading New Chemotherapy Technique Carries Risks for Peritoneal Mesothelioma Patients »

Mesothelioma Patients May Benefit from ‘Aesthetic Support’

When it comes to coping with the treatment and side effects of a cancer like malignant mesothelioma, looks matter – especially to female patients. That is the message of a new Italian study on the impact of an “aesthetic care” program for hospitalized cancer patients. The objective of the study, published in the journal Frontiers in Psychology, was to evaluate a support program called “Health in the Mirror”, that provides various “aesthetic interventions” to help cancer patients feel better about their bodies during cancer treatment. How Does Mesothelioma Change the Body? Cancer can have a significant impact not only on how patients with mesothelioma or other cancers feel, but also on how they look. Mesothelioma patients may lose weight. Patients … Continue reading Mesothelioma Patients May Benefit from ‘Aesthetic Support’ »

Diagnosing Mesothelioma with BAP1 Testing: Does it Work?

Tests for the presence or absence of the BAP1 tumor-suppressor protein are likely to continue to play a pivotal role in the diagnosis of malignant mesothelioma. A new evaluation of worldwide studies including more than 1,800 mesothelioma patients found that people who were missing the BAP1 protein almost always had mesothelioma, while those whose cells were still producing BAP1 were not necessarily in the clear. Understanding BAP1 The BRCA1 associated protein 1 (BAP1) gene is responsible for producing a protein (BAP1) that helps suppress the growth of mesothelioma tumors. In some people, the BAP1 gene is mutated, leading to a loss of production of the BAP1 protein. This is known as BAP1 cancer syndrome. People with the BAP1 cancer syndrome … Continue reading Diagnosing Mesothelioma with BAP1 Testing: Does it Work? »

Get your free copy of
“Surviving Mesothelioma” Today!